Non-small cell lung cancer squamous · 6 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Carboplatin and Gemcitabine (GCb) and Durvalumab N/A - protocol | — | R 269 756 | 28d | — | — | ~12 | ~R 2 132 630 indirect | — |
Cisplatin and Gemcitabine (GC) and Durvalumab Variant #02 | — | R 267 040 | 28d | — | ~12.9 mo | ~8 | ~R 1 346 116 PFS proxy · indirect | 3 |
Carboplatin and Paclitaxel (CP) and Durvalumab Variant #03 | — | R 232 682 | 28d | ~10.2 mo | — | ~6 | ~R 869 291 PFS proxy · indirect | 1 |
Cisplatin and Gemcitabine (GC) and Pembrolizumab Variant #01 | — | R 85 626 | 21d | — | — | 36 | R 2 992 297 PFS proxy | 1 |
Carboplatin and Paclitaxel (CP) and Nivolumab Variant #01 Partial | — | R 2 645 | 21d | — | — | 13 | R 10 579 PFS proxy | 1 |
Cisplatin and Docetaxel (DC) and Nivolumab Variant #01 Partial | — | R 2 389 | 21d | — | — | ~3 | ~R 7 167 PFS proxy · indirect | 1 |
6 of 6 regimens shown